Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes

Neurology

Volumn 49, Issue 2, 1997, Pages 385-392

  Pette, M ^a,b   Pette, D F ^a   Muraro, P A ^a   Farnon, E ^a   Martin, R ^a,b   McFarland, H F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030864154     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.385     Document Type: Article

References (26)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
2. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:655-661.
3. Paty DW, Li DKB, The UCB MS/MRI Study Group, The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
4. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-187.
5. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995;61:185-193.
6. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-154.
7. Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 1993;43:2080-2087.
8. Rep MH, Hintzen RQ, Polman CH, van Lier RA. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996;67:111-118.
9. Abu-khabar KS, Armstrong JA, Ho M. Type I interferons (IFN-α and -β) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukoc Biol 1993;52:165-172.
10. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
11. Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990;40:1770-1776.
12. Jaraquemada D, Martin R, Rosen-Bronson S, Flerlage M, McFarland HF, Long EO. HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J Immunol 1990;145:2880-2885.
13. Pette M, Pette DF, Muraro PA, Martin R, McFarland HF. In vitro modulation of human, autoreactive MBP-specific CD4+ T cell clones by cyclosporin A. J Neuroimmunol 1997;76:91-99.
14. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995;32:121-182.
15. Fritz RB, Skeen MJ, Chou CHJ, Zamvil SS. Localization of an encephalitogenic epitope for the SJL mouse in the N-terminal region of myelin basic protein. J Neuroimmunol 1990;26:239-243.
16. Smith KA. Cell growth signal transduction is quantal. Ann NY Acad Sci 1995;766:263-271.
17. Khan OA, Xia Q, Bevor CT, Johnson KP, Panitch HS, Dhib-Jalbut SS. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996;46:1639-1643.
18. Jonak GJ, Friedland BK, Anton ED, Knight E Jr. Regulation of c-myc RNA and its protein in Daudi cells by interferon-beta J Interferon Res 1987;7:41-52.
19. Rudick RA, Ransohoff RM, Peppler R, Medendrop Vander-Brug S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-627.
20. Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992;148:1143-1148.
21. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995;45:2173-2177.
22. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trichieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048.
23. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954.
24. Karpus WJ, Lukacs NW, McRae BL, Stricter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1996;155:5003-5010.
25. Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis. J Immunol 1996;156:5-7.
26. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258.